| Patent(s) and the Corresponding Patented Drug(s) |
Top |
| United States Patent and Trademark Office (USPTO) |
| Patent ID |
US9388139 |
| Title |
Derivatives of celeboxib, use thereof and preparation thereof |
| Abstract |
Derivatives of celecoxib that lack cyclooxygenase inhibitory activity but have improved PDE5 inhibitory activity are provided along with pharmaceutical compositions containing them for the treatment or prevention of cancer. Such compounds are expected to have reduced toxicity compared with celecoxib and other cyclooxygenase inhibitors, and greater efficacy compared with conventional PDE5 inhibitors. Derivatives of celecoxib are also suitable for treating chronic inflammatory conditions, erectile dysfunction, pulmonary hypertension, congestive heart failure, and enhancement of cognitive function. |
| Applicant(s) |
German University; Southern Research Institute |
| Representative Drug(s) |
D0SG9Q |
Drug Info
|
IC50 > 50000nM |
[1] |
| Patent ID |
US9067945 |
| Title |
Selective phosphodiesterase 9A inhibitors as medicaments for improving cognitive processes |
| Abstract |
The invention relates to the use of selective phosphodiesterase 9A (PDE9A) inhibitors for producing medicaments for improving perception, concentration, cognitive processes, learning and/or memory. |
| Applicant(s) |
Boehringer Ingehleim International GmbH |
